Propanc Biopharma Stock Probability of Future Pink Sheet Price Finishing Under 0.0703
| PPCB Stock | USD 0.0002 0.0001 33.33% |
Propanc |
Propanc Biopharma Target Price Odds to finish below 0.0703
The tendency of Propanc Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 0.07 after 90 days |
| 0.0002 | 90 days | 0.07 | close to 99 |
Based on a normal probability distribution, the odds of Propanc Biopharma to stay under $ 0.07 after 90 days from now is close to 99 (This Propanc Biopharma probability density function shows the probability of Propanc Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Propanc Biopharma price to stay between its current price of $ 0.0002 and $ 0.07 at the end of the 90-day period is about 97.0 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 3.23 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Propanc Biopharma will likely underperform. Additionally Propanc Biopharma has an alpha of 0.9284, implying that it can generate a 0.93 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Propanc Biopharma Price Density |
| Price |
Predictive Modules for Propanc Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Propanc Biopharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Propanc Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Propanc Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Propanc Biopharma is not an exception. The market had few large corrections towards the Propanc Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Propanc Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Propanc Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.93 | |
β | Beta against Dow Jones | 3.23 | |
σ | Overall volatility | 0.00006 | |
Ir | Information ratio | 0.05 |
Propanc Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Propanc Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Propanc Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Propanc Biopharma is way too risky over 90 days horizon | |
| Propanc Biopharma has some characteristics of a very speculative penny stock | |
| Propanc Biopharma appears to be risky and price may revert if volatility continues | |
| Propanc Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
Propanc Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Propanc Pink Sheet often depends not only on the future outlook of the current and potential Propanc Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Propanc Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 220.4 M |
Propanc Biopharma Technical Analysis
Propanc Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Propanc Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Propanc Biopharma. In general, you should focus on analyzing Propanc Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Propanc Biopharma Predictive Forecast Models
Propanc Biopharma's time-series forecasting models is one of many Propanc Biopharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Propanc Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Propanc Biopharma
Checking the ongoing alerts about Propanc Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Propanc Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Propanc Biopharma is way too risky over 90 days horizon | |
| Propanc Biopharma has some characteristics of a very speculative penny stock | |
| Propanc Biopharma appears to be risky and price may revert if volatility continues | |
| Propanc Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.